Sanabani Sabri Saeed
Laboratory of Medical Investigation LIM 03, Hospital das Clínicas (HCFMU), School of Medicine, University of São Paulo, São Paulo, Brazil.
Clin Lymphoma Myeloma Leuk. 2025 Feb;25(2):e82-e89. doi: 10.1016/j.clml.2024.08.008. Epub 2024 Aug 27.
The gut microbiome (GMB), which is made up of various microorganisms, plays a crucial role in maintaining the health of the host. Disruptions in this delicate ecosystem, known as microbial dysbiosis, have been linked to various diseases, including hematologic malignancies such as lymphoma. This review article explores the complex relationship between the GMB and the development of lymphoma and highlights its implications for diagnostic and therapeutic approaches. It discusses how GMB influences lymphoma development directly through the presence of certain microorganisms and indirectly through changes in the immune system. The clinical relevance of GMB is highlighted and its potential utility for diagnosis, predicting treatment outcomes and developing personalized therapeutic strategies for lymphoma patients is demonstrated. The review also looks at microbiome-targeted interventions such as fecal microbiome transplantation and dietary modification, which have shown promise for treating microbial dysbiosis and improving patient outcomes. In addition, it highlights the analytical challenges and the need for further research to fully elucidate the mechanistic functions of the GMB in the context of lymphoma. This review emphasizes the critical role of GMB in lymphomagenesis and its potential for the development of diagnostic and therapeutic strategies.
肠道微生物群（GMB）由多种微生物组成，在维持宿主健康方面发挥着关键作用。这种微妙生态系统的破坏，即微生物失调，与包括淋巴瘤等血液系统恶性肿瘤在内的各种疾病有关。这篇综述文章探讨了GMB与淋巴瘤发展之间的复杂关系，并强调了其对诊断和治疗方法的影响。它讨论了GMB如何通过某些微生物的存在直接影响淋巴瘤的发展，并通过免疫系统的变化间接影响淋巴瘤的发展。强调了GMB的临床相关性，并展示了其在淋巴瘤患者诊断、预测治疗结果和制定个性化治疗策略方面的潜在效用。该综述还探讨了针对微生物群的干预措施，如粪便微生物群移植和饮食调整，这些措施已显示出治疗微生物失调和改善患者预后的前景。此外，它强调了分析挑战以及进一步研究以充分阐明GMB在淋巴瘤背景下的机制功能的必要性。这篇综述强调了GMB在淋巴瘤发生中的关键作用及其在诊断和治疗策略发展方面的潜力。
